IV
119THCONGRESS
1
STSESSION H. RES. 394
Expressing support for the designation of July 16, 2025, as ‘‘Glioblastoma
Awareness Day’’.
IN THE HOUSE OF REPRESENTATIVES
MAY6, 2025
Mr. W
ILLIAMSof Texas (for himself, Mr. MAST, Ms. SCHAKOWSKY, and Mr.
A
UCHINCLOSS) submitted the following resolution; which was referred to
the Committee on Energy and Commerce
RESOLUTION
Expressing support for the designation of July 16, 2025,
as ‘‘Glioblastoma Awareness Day’’.
Whereas it is estimated that more than 13,000 Americans
will be diagnosed with glioblastoma in 2025;
Whereas glioblastoma is—
(1) the most common malignant (cancerous) brain
tumor, accounting for approximately
1
⁄2of all primary
malignant brain tumors; and
(2) the most aggressive, complex, difficult to treat,
and deadly type of brain tumor;
Whereas it is estimated that more than 10,000 individuals in
the United States will succumb to glioblastoma each year;
VerDate Sep 11 2014 22:19 May 06, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6300 E:\BILLS\HR394.IH HR394
ssavage on LAPJG3WLY3PROD with BILLS 2
•HRES 394 IH
Whereas the 5-year survival rate for glioblastoma patients is
only 6.9 percent, and the median length of survival for
glioblastoma patients is only 8 months;
Whereas glioblastoma is described as a disease that affects
the ‘‘essence of self’’, as the treatment and removal of
glioblastoma presents significant challenges due to the
uniquely complex and fragile nature of the brain, the pri-
mary organ in the human body that controls not only
cognitive ability, but also the actions of every organ and
limb;
Whereas patients and caregivers play a critical role in fur-
thering research for glioblastoma;
Whereas, relative to other types of cancers, brain cancer pa-
tients pay the second highest out-of-pocket costs for med-
ical services in both the initial and end-of-life phases of
care;
Whereas, although research advances may fuel the develop-
ment of new treatments for glioblastoma, challenging ob-
stacles to accelerating progress toward new treatments
for glioblastoma remain, and there are no screening or
early detection methods;
Whereas, in 2021, significant changes were made to the mo-
lecular characteristics of a glioblastoma diagnosis, neces-
sitating critical biomarker testing for patients suspected
of having a possible glioblastoma;
Whereas, although glioblastoma was first described in medical
and scientific literature in the 1920s, and despite its dev-
astating prognosis, only 5 drugs and 1 medical device
have been approved by the Food and Drug Administra-
tion to specifically treat glioblastoma since the 1920s,
VerDate Sep 11 2014 22:19 May 06, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6300 E:\BILLS\HR394.IH HR394
ssavage on LAPJG3WLY3PROD with BILLS 3
•HRES 394 IH
and the mortality rates associated with glioblastoma have
changed little during the past 30 years;
Whereas, since the first Glioblastoma Awareness Day, the
National Cancer Institute established the Glioblastoma
Therapeutics Network (referred to in this preamble as
‘‘GTN’’) in 2020 as part of a national infrastructure to
enhance and support the discovery and development of
glioblastoma therapies available for multi-institutional
GTN teams to drive therapeutic agents through pre-
clinical studies and early phase clinical trials, which are
necessary to rapidly evaluate potential treatments to ad-
vance toward cures and improved quality of life;
Whereas there is a need for greater public awareness of glio-
blastoma, including awareness of both—
(1) the urgent unmet medical needs of glioblastoma
patients; and
(2) the opportunities for research of, and treatment
advances for, glioblastoma; and
Whereas the House of Representatives supports designating
July 16, 2025, as ‘‘Glioblastoma Awareness Day’’: Now,
therefore, be it
Resolved, That the House of Representatives— 1
(1) expresses support for the designation of 2
‘‘Glioblastoma Awareness Day’’; 3
(2) encourages increased public awareness of 4
glioblastoma; 5
(3) honors the individuals who have died from 6
the devastating disease of glioblastoma or are cur-7
rently living with the disease; 8
VerDate Sep 11 2014 22:19 May 06, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\HR394.IH HR394
ssavage on LAPJG3WLY3PROD with BILLS 4
•HRES 394 IH
(4) supports efforts to develop better treat-1
ments for glioblastoma that will improve the long- 2
term prognosis for, and the quality of life of, individ-3
uals diagnosed with the disease; 4
(5) recognizes the importance of molecular bio-5
marker testing to the diagnosis and treatment of 6
glioblastoma; 7
(6) expresses support for the individuals who 8
are battling brain tumors, as well as the families, 9
friends, and caregivers of those individuals; 10
(7) urges a collaborative approach to brain 11
tumor research among governmental, private, and 12
nonprofit organizations, which is a promising means 13
of advancing the understanding and treatment of 14
glioblastoma; and 15
(8) encourages continued investments in glio-16
blastoma research and treatments, including through 17
the Glioblastoma Therapeutics Network and other 18
existing brain tumor research resources. 19
Æ
VerDate Sep 11 2014 22:19 May 06, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6301 E:\BILLS\HR394.IH HR394
ssavage on LAPJG3WLY3PROD with BILLS